Funded with Support from

In this webinar, Drs. Kumar, Yam, Stager, and Dumitrescu provide updates on pediatric ophthalmology/strabismus geared toward comprehensive ophthalmologists.

In this interview from AAO 2020 Virtual, Dr. Michael Repka discusses highlights from the 2020 Jackson Memorial Lecture, Amblyopia Outcomes through Clinical Trials and Practice Measurement: Room for Improvement.

This week, a gene therapy for Leber hereditary optic neuropathy gains orphan drug designation, a novel eye drop for presbyopia is cleared for phase 2 trials and a common antidepressant shows early promise for amblyopia.

Multicenter prospective, randomized amblyopia screening and treatment trials have created a new body of evidence upon which to base clinical practices of screening, diagnosis, and treatment. This collection of content, based on IRIS Registry measure IRIS50: Amblyopia: Interocular Visual Acuity, reviews the best evidence-based approach for diagnosing and treating amblyopia while advocating for early, appropriate screening.

Early diagnosis of ocular changes associated with amblyopia is crucial for good visual prognosis because it allows treatment to begin at a stage where the visual neurological pathways are still amenable to stimulation, recovery, and reversal of cortical damage.

Researchers assessed whether amblyopia affects self-perception in young children and correlates with defects in vision and fine motor skills.

The studies completed by the Pediatric Eye Disease Investigator Group and others have clarified several questions and improved management and patient outcomes of both moderate and severe amblyopia. Selected medicolegal considerations, applicable as well beyond amblyopia management, are considered.

Investigators evaluated whether people with AMD and a history of amblyopia have equal severity of AMD in both eyes.

This lecture from Pediatric Ophthalmology 2017 presents the case of a 9-year-old boy whose left eye has drifted up since birth, with a right eye that doesn't seem to elevate.